Phase 4CompletedAge-related condition
The Effect of Vitamin K2 on Bone Turnover
Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study
- Sponsor
- Eisai Limited (Industry)
- Enrollment
- 131 enrolled
- Conditions
- Osteoporosis
- Interventions
- Menatetrenone (Vitamin K2)
- Ages
- adults, older adults
- Registry
- NCT00548509
Full record on ClinicalTrials.gov
From the registry
To investigate the effect of menatetrenone on bone turnover in postmenopausal patients with osteoporosis. One month of menatetrenone therapy enhanced the secretion and gamma-carboxylation of osteocalcin. Moderate increases of bone resorption and formation markers were observed after 6 months. These changes may contribute to fracture prevention in patients with osteoporosis.
Primary outcomes
- Gamma-carboxylation
History
Last registry update
Primary completion
Registered
Started